(redirected from Factor V Leiden mutation)
  • noun

Synonyms for mutation

Synonyms for mutation

the process or result of making or becoming different


Synonyms for mutation

(biology) an organism that has characteristics resulting from chromosomal alteration

a change or alteration in form or qualities

References in periodicals archive ?
Chen Y, Stanford MR, Wallace GR et al: Factor V Leiden mutation does not correlatewith retinalvascularocclusionin whitepatients with Behcet's disease.
The C [right arrow] T change at position 1690 would produce a factor V deficiency, whereas the factor V Leiden mutation (G [right arrow]A at position 1691) causes a thrombophilic predisposition.
Patients with a lupus anticoagulant should be evaluated directly with a genetic assay to determine if the factor V Leiden mutation is present.
Hyperhomocysteinaemia and factor V Leiden mutation are associated with Budd-Chiari syndrome.
The Factor V Leiden mutation is the most common genetic thrombophilia: the heterozygous form, found in 5%-8% of the normal population, increases the risk of VTE fivefold, whereas the rarer homozygous form confers an 18-fold risk increase.
People who have the factor V Leiden mutation are at somewhat higher than average risk for a type of clot that forms in large veins in the legs (deep venous thrombosis) or a clot that travels through the bloodstream and lodges in the lungs (pulmonary embolism).
Individuals heterozygous for the factor V Leiden mutation have a sevenfold higher risk to develop venous thrombosis than wild-type (WT) individuals (1).
Activated C-reactive protein resistance not related to a factor V Leiden mutation is known to be a risk factor for venous thrombosis, and an elevated C-reactive protein level, as seen with the resistance in this study, is a predictor of cardiovascular events.
The factor V Leiden mutation is a common cause of unprovoked venous thrombosis in the white population.
Both men and women with factor V Leiden mutation face a 30% lifetime risk of venous thromboembolism (VTE), and the prevalence in Europeans ranges from 5% to 15%.
To date, the cross-linking technology has been applied to detection of bacterial pathogens (1), quantification of viral DNA (2), assessment of gene dosage and methylation status (3), and detection of single-nucleotide polymorphisms (SNPs), specifically the factor V Leiden mutation, G1691A, and the two most common mutations that are linked to hereditary hemochromatosis, G845A and C187G (4,5).
Cushman was quick to note that any role of testing for factor V Leiden mutation in making decisions about prescribing estrogen plus progestin in postmenopausal women "will require further study.